

BenevolentAI**Issue of Equity and Total Voting Rights**

London, UK, 3 December 2024 - BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery and development, announces that, on 2 December 2024, 390,841 new class A redeemable shares (the "Ordinary Shares") have been issued within the Company's authorised share capital for the settlement of certain granted and vested restricted stock units under the Company's employee share schemes. As a result, as of 2 December 2024, the issued share capital of the Company amounts to EUR 145,517,144.

In accordance with article 14 of the Luxembourg law of 11 January 2008 on transparency requirements in relation to information about issuers whose securities are admitted to trading on a regulated market, the Company confirms that as at 2 December 2024 its issued share capital consists of 143,017,144 Ordinary Shares without nominal value and 2,500,000 convertible class B shares (the "Sponsor Shares") without nominal value. Out of the total number of shares issued by the Company, 20,686,419 Ordinary Shares are currently held in treasury and do not, consequently, carry voting rights. The difference between the total number of shares (145,517,144) and the treasury shares (20,686,419) is 124,830,725. Each one of these 124,830,725 shares entitles its holder to one vote.

ENDS

Enquiries:**Investors:**

Fleur Wood – VP Investor Relations

investors@benevolent.ai

Company Secretary:

Judit Molnar – Deputy Company Secretary

cosec@benevolent.ai